K. Webster

发表

Prolonged Disease-Free and Treatment-Free Survival in Platinum-Resistant Ovarian Cancer Following Extended (> 1 Year) Administration of Single-Agent Paclitaxel: A Case Report and Discussion of Potential Clinical Implications

M. Markman, K. Webster, B. Kulp, 2005, Cancer investigation.

Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers

M. Markman, J. Belinson, K. Webster, 2004, Journal of Cancer Research and Clinical Oncology.

Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia.

P. Elson, M. Markman, J. Belinson, 2003, Gynecologic oncology.

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.

M. Markman, A. Kennedy, J. Belinson, 2000, Gynecologic oncology.

Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.

R. Alvarez, P. Rose, J. Curtin, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

R. Buller, R. Mannel, P. Rose, 2003, Gynecologic oncology.

Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.

M. Markman, J. Belinson, K. Webster, 2003, Gynecologic oncology.

Tumor distribution and survival in six patients with brain metastases from cervical carcinoma.

G. Barnett, J. Suh, A. Kennedy, 2001, Gynecologic oncology.

The effect of radiation therapy on brain metastases from endometrial carcinoma: a retrospective study.

G. Barnett, J. Suh, J. Belinson, 2001, Gynecologic oncology.

Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Serum CA-125 measurements > 65 U/mL. Clinical value.

L. Blumenson, J. Belinson, G. Eltabbakh, 1997, The Journal of reproductive medicine.

Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions

M. Markman, J. Belinson, K. Webster, 2003, Journal of Cancer Research and Clinical Oncology.

Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.

A. Kennedy, J. Belinson, K. Webster, 1999, Gynecologic oncology.

Evidence that a “treatment-free interval of less than 6 months” does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma

M. Markman, J. Belinson, A. Kennedy, 1998, Journal of Cancer Research and Clinical Oncology.

Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.

G. Sutton, M. Markman, J. Hurteau, 1998, Gynecologic oncology.

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.

M. Markman, A. Kennedy, J. Belinson, 1997, Gynecologic oncology.

Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum

E. Borden, B. Jacobs, D. Lindner, 2004, Oncology.

Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.

P. Escobar, P. Rose, M. Markman, 2004, Gynecologic oncology.

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.

M. Markman, J. Belinson, K. Webster, 2003, Gynecologic oncology.

Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.

M. Markman, A. Kennedy, J. Belinson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of paclitaxel plus megestrol acetate in patients with paclitaxel-refractory ovarian cancer.

M. Markman, A. Kennedy, J. Belinson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Paclitaxel-Assoc iated H ypersensitivity R eactions: Experience o f t he G ynecologic O ncology P rogram o f t he Cleveland C linic C ancer C enter

M. Markman, J. Belinson, A. Kennedy, 2000 .

Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.

M. Markman, A. Kennedy, J. Belinson, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

M. Markman, A. Kennedy, J. Belinson, 2000, Gynecologic oncology.

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

P. Rose, I. Horowitz, W. Mcguire, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors.

A. Kennedy, J. Belinson, K. Webster, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.

L. Rybicki, M. Markman, J. Belinson, 1998, Gynecologic oncology.

Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.

S. Lichtman, H. Homesley, G. Omura, 1998, Gynecologic oncology.

Radical hysterectomy for cervical cancer: the effect of shorter length of stay on outcome.

L. Tuason, J. Belinson, A. Kennedy, 1995, Cleveland Clinic journal of medicine.

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

R. Burger, Joan L. Walker, D. Armstrong, 2006, Gynecologic Oncology.

Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.

M. Markman, J. Belinson, K. Webster, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.

L. Rybicki, M. Markman, J. Belinson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone.

M. Markman, A. Kennedy, J. Belinson, 1996, Gynecologic oncology.

Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer

P. Escobar, M. Markman, J. Belinson, 2003, Journal of Cancer Research and Clinical Oncology.

Methotrexate in Advanced Endometrial Carcinoma: A Phase II Trial of the Gynecologic Oncology Group

K. Hatch, H. Muss, J. Soper, 1990, American journal of clinical oncology.

The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.

M. Markman, A. Kennedy, J. Belinson, 2000, Gynecologic oncology.

Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.

M. Markman, A. Kennedy, J. Belinson, 1998, Gynecologic oncology.

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.

M. Markman, A. Kennedy, J. Belinson, 1996, Gynecologic oncology.

Gynecologic cancer in the very elderly.

A. Kennedy, K. Webster, J. S. Flagg, 1989, Gynecologic oncology.

Experience with pelvic washings in stage I and II endometrial carcinoma.

A. Kennedy, K. Webster, G. Peterson, 1987 .

Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.

F. Valea, W. Andersen, J. Blessing, 1997, Gynecologic oncology.

Clinical features of hypersensitivity reactions to carboplatin.

P. Elson, A. Kennedy, J. Belinson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix

G. Sutton, J. Blessing, K. Webster, 1989, Investigational new drugs.

Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.

J. Rader, C. Dunton, N. Husseinzadeh, 2002, Gynecologic oncology.

Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma

C. Michener, M. Markman, K. Webster, 2005, Journal of Cancer Research and Clinical Oncology.

Circadian-timed Combination Doxorubicin-cisplatin Chemotherapy for Advanced Endometrial Carcinoma: A Phase Ii Study of the Gynecologic Oncology Group

L. Twiggs, H. Homesley, J. Blessing, 1993 .

Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia

M. Markman, J. Belinson, A. Kennedy, 2000, Journal of Cancer Research and Clinical Oncology.

Ovarian clear cell adenocarcinoma.

C. Biscotti, W. R. Hart, A. Kennedy, 1989, Gynecologic oncology.

Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias.

M. Markman, A. Kennedy, J. Belinson, 1999, Gynecologic oncology.

Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies

M. Markman, J. Belinson, A. Kennedy, 2001, Journal of Cancer Research and Clinical Oncology.

Expanded E xperience W ith a n I ntradermal S kin T est t o Predict f or t he P resence o r A bsence o f C arboplatin Hypersensitivity

M. Markman, J. Belinson, K. Webster, 2003 .

Gastrointestinal toxicity is not a major complication of standard dose paclitaxel therapy.

M. Markman, A. Kennedy, J. Belinson, 1999, Gynecologic oncology.

Clinical F eatures o f H ypersensitivity Reactions t o C arboplatin

P. Elson, M. Markman, J. Belinson, 1999 .

Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.

L. Rybicki, D. Kushner, M. Markman, 2000, Gynecologic oncology.

A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

P. Rose, W. Creasman, J. Blessing, 1996, Gynecologic oncology.

Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids.

Yan Xu, Y. Xu, B. Schwartz, 2001, Analytical biochemistry.

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

M. Markman, J. Belinson, K. Webster, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results.

M. Markman, A. Kennedy, J. Belinson, 2000, Gynecologic oncology.

Circadian‐Timed Combination Doxorubicin‐Cisplatin Chemotherapy for Advanced Endometrial Carcinoma: A Phase II Study of the Gynecologic Oncology Group

L. Twiggs, H. Homesley, J. Blessing, 1990, American journal of clinical oncology.

Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis

M. Markman, J. Belinson, A. Kennedy, 2005, Journal of Cancer Research and Clinical Oncology.

Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.

M. Markman, J. Belinson, K. Webster, 2004, Gynecologic oncology.

An effective and more convenient drug regimen for prophylaxis gainst paclitaxel-associated hypersensitivity reactions

Maurie Markman, M. Markman, J. Belinson, 1999, Journal of Cancer Research and Clinical Oncology.

Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.

M. Markman, J. Belinson, A. Kennedy, 2000, Gynecologic oncology.

Single- and Multiple-Dose Pharmacokinetics of Methylphenidate Administered as Methylphenidate Transdermal System or Osmotic-Release Oral System Methylphenidate to Children and Adolescents With Attention Deficit Hyperactivity Disorder

D. Pierce, A. Katic, K. Webster, 2010, Journal of clinical psychopharmacology.

Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma

M. Markman, J. Belinson, A. Kennedy, 1999, Journal of Cancer Research and Clinical Oncology.

A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

S. Waggoner, K. Darcy, D. Benbrook, 2007, Gynecologic oncology.

Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: Effect of treatment and incidence of intracranial metastases

R. Livingston, G. Budd, K. Webster, 1983, Journal of surgical oncology.

The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.

M. Markman, J. Belinson, A. Kennedy, 1999, Gynecologic oncology.

Echinomycin (NSC 526417) in recurrent and metastatic nonsquamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.

H. Muss, P. Hanjani, J. Blessing, 1992, American journal of clinical oncology.

Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions.

M. Markman, A. Kennedy, J. Belinson, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pelvic washings for cytologic analysis in endometrial adenocarcinoma.

A. Kennedy, K. Webster, C. Núñez, 1993, The Journal of reproductive medicine.

Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma.

D. Seifer, A. Kennedy, K. Webster, 1988, Cleveland Clinic journal of medicine.

Hormonal evaluation of premature menarche produced by a follicular cyst.

K. Webster, R. G. Wieland, M. Hallberg, 1976, American Journal of Obstetrics and Gynecology.

Leuprolide in the treatment of endometrial cancer.

M. Markman, A. Kennedy, J. Belinson, 1997, Gynecologic Oncology.

Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.

M. Markman, A. Kennedy, J. Belinson, 1997, Seminars in oncology.